CLINICAL TRIALS AT ENANTA

Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active research and development programs in areas such as respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), hepatitis B virus (HBV), and human metapneumovirus (hMPV).

If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at nadda@enanta.com.

Learn more about any of our clinical trials described below by clicking the ClinicalTrials.gov. identifier listed below the description of the trial.


Non-Alcoholic Steatohepatitis

A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)
Clinicaltrials.gov identifier: NCT04378010

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects
ClinicalTrials.gov Identifier: NCT04559126


Respiratory Syncytial Virus

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Clinicaltrials.gov identifier: NCT04196101

Hepatitis B Virus

A study of EDP-514 in Healthy Subjects (Part 1) and Patients with Chronic Hepatitis B Virus Infection (Part 2)
Clinicaltrials.gov identifier: NCT04008004

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
ClinicalTrials.gov Identifier: NCT04470388